AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02073266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.
Study NCT02924415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-care support
Description: Psychoeducation treatment based on telemedicine
Study NCT02924415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard care
Study NCT00636987 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biocor and Biocor Supra valves
Description: Replacement for a diseased, damaged, malformed aortic or mitral heart valve
Study NCT04306679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animation clips
Description: The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
Study NCT04306679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Instructions
Description: Routine preoperative preparations, which included a section on pain assessment instructions.
Study NCT00704665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: 10 ug/kg/day or 25 ug/kg/day
Study NCT00704665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relaxin
Description: Placebo
Study NCT02092038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: craniotomy and tumor resection
Description: maximal safe resection
Study NCT03443323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training - Tier 2 (OST-T2)
Description: OST-T2 is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-T2 and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
Study NCT02880501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proximal femoral nail antirotation
Description: Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
Study NCT01051284 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife radiation and gemcitabine
Description: 25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
Study NCT02712775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00629083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulkamid
Description: Bulking injection with Bulkamid injection device
Study NCT00629083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contigen
Description: Transurethral bulking injection
Study NCT00534534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated behavioural intervention without any drugs
Description: All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
Study NCT03104582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP Drainage
Description: When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
Study NCT03104582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTBD Drainage
Description: When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
Study NCT01482702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss intervention
Description: Behavioral weight loss intervention
Study NCT01482702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Behavioral weight loss intervention
Study NCT01482702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: Behavioral weight loss intervention
Study NCT03124043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livongo for Diabetes program
Description: See description in arm/group description.
Study NCT02970773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban Oral Tablet
Description: oral application of Xarelto
Study NCT02226354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ahiflower oil
Description: 9.73 ml per day for 28 days
Study NCT02226354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed oil
Description: 9.73ml per day for 28 days
Study NCT01883141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiological Study
Description: Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
Study NCT03808961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: 100mg tablets twice daily
Study NCT03808961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Niacinamide
Description: 100mg tablets twice daily
Study NCT03808961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily
Study NCT03834948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176
Description: Humanized monoclonal antibody (mAb) targeting CD47
Study NCT03834948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Paclitaxel
Description: Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel
Study NCT03834948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Pembrolizumab
Description: Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
Study NCT02696187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KOLwebben
Description: KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
Study NCT04195126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb haemadsorption device
Description: CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
Study NCT02551627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test Product
Description: MMN fortified beverage powder.
Study NCT02551627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Isocaloric beverage powder without micronutrient fortification.
Study NCT01285687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
Study NCT03044639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Emulsions, Intravenous
Description: The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
Study NCT04920227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification;
Description: Group A: class combined with phacoemulsification
Study NCT02329366 — intervention group
Intervention type: OTHER
Intervention: Specimen Collection
Description: . In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
Study NCT04874272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chaplain led post-code debrief
Description: an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
Study NCT01649479 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Antiphospholipid antibody tests
Description: Each patient will be tested for antiphospholipid antibodies.
Study NCT01649479 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Thrombophilia bloodwork
Description: Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII
Study NCT01649479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychiatric evaluation
Description: During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
Study NCT00710190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheos Baroreflex Hypertension Therapy System
Description: This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
Study NCT01794780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA based treatment: indacaterol
Description: LABA based treatment: indacaterol
Study NCT03103815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivita
Description: In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
Study NCT05052281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) Course
Description: The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress.
Study NCT05052281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just in Time Intervention (JITI) Content
Description: Participants will also receive additional MB intervention content in the form of just-in-time text messages, which will be sent to participants' smartphones every other day for up to 12 weeks. During the current trial, participants will receive text message prompts with links to additional stress reduction content based on a combination of their objective (sensor) and subjective (EMA) stress responses from the previous day.
Study NCT05052281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biostamp nPoint Device
Description: During the intervention period, participants will be asked to wear the BioStamp nPoint sensor, daily, while engaging in their usual activities (e.g., sleep, showering, exercise). The BioStamp Sensor is a thin, wearable patch, equipped with wireless high-range 6-axis gyroscope + accelerometer, and sEMG and ECG sensors, that adheres to the skin using a disposable medical-grade adhesive sticker (with adhesive similar to Band-Aid).
Study NCT01479491 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
Study NCT05052281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biostamp nPoint Device
Description: During the intervention period, participants will be asked to wear the BioStamp nPoint sensor, daily, while engaging in their usual activities (e.g., sleep, showering, exercise). The BioStamp Sensor is a thin, wearable patch, equipped with wireless high-range 6-axis gyroscope + accelerometer, and sEMG and ECG sensors, that adheres to the skin using a disposable medical-grade adhesive sticker (with adhesive similar to Band-Aid).
Study NCT02852083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 25 mg once daily, p.o.
Study NCT02852083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: 3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
Study NCT02852083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan 250 mg twice daily, p.o.
Study NCT02852083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 250 mg twice daily p.o.
Study NCT01010100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay, BAYG5421)
Description: 50 mg TID
Study NCT01010100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg TID
Study NCT01898078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib ECT
Study NCT02466542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Patients will receive regular general anesthesia
Study NCT02466542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol group
Description: Patients will receive regular general anesthesia plus esmolol infusion
Study NCT03299062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cytology and Immunohistochemistry
Description: Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
Study NCT03299062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cytology and Immunohistochemistry
Description: Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
Study NCT02480686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF+PEG+RBV
Description: Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study NCT01566786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
Study NCT01566786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
Study NCT03770273 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sarilumab
Description: Sarilumab is a fully human anti-IL-6Rα monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling.
Study NCT03770273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04089774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA)
Description: Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
Study NCT03360279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular balloon
Description: Randomization: to use regular balloon to treat stent graft restenosis
Study NCT03360279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DCB (paclitaxel-coated balloon)
Description: Randomization: to use DCB (paclitaxel-coated balloon, Ranger, Boston-Scientific) to treat stent graft restenosis. The paclitaxel dose is 2 ug/mm2 delivered with the Ranger drug-coated balloon.
Study NCT02829710 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nurse-driven sedation protocol
Description: The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
Study NCT02071160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
Study NCT00901641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CogniFit Personal Coach®
Description: The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
Study NCT02188732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBHH+AT
Description: Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk.
Study NCT02188732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBHH+SMT
Description: Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
Study NCT02188732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBHH
Description: Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).